GrouseMan wrote:- I posed this as perhaps why this could be a reason some studies show the use of curcumin to be active against some cancers, particularly in the case as a potential preventative as so many studies have shown.
Yes to that!
This article is great food for thought.
About taking curcumin before undergoing a treatment with a PD-1/ PD-L1 inhibitor, I was thinking the following: PD-1/ PD-L1 checkpoint inhibitors (pembro, nivo, atezo, durvalumab, avelumab, etc.) work better against tumours with *high* PD-1/ PD-L1 expression; that high expression predicts benefit from it, the drugs go against tissues with high values of PD-1 /PD-L1. And some trials run a test to determine PD-1/ PD-L1 expression, to determine inclusion.
So (and the following is more a question than an assert): might be that one doesn't want to "reduce PD-L1 abundance" before/when starting a therapy with this inhibitors, or at least maybe when initiating therapy with anti PD-L1
(the ones that go against the ligand on the surface of tumor cells, specifically, like atezo, durvalumab and avelumab; not pembro and nivo).
On the other hand, when already on an anti PD-L1
, curcumin would add potency to the anti -pd-L1 one is taking?
And so nice to see you, GrouseMan! Happy your wife is doing quite well : )